Qtrilmet

RSS

metformin hydrochloride / saxagliptin / dapagliflozin

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Qtrilmet has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 09/10/2020

Authorisation details

Product details
Name
Qtrilmet
Agency product number
EMEA/H/C/004910
Active substance
  • metformin hydrochloride
  • Saxagliptin
  • dapagliflozin
International non-proprietary name (INN) or common name
metformin hydrochloride / saxagliptin / dapagliflozin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BD
Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
11/11/2019
Contact address

AstraZeneca AB
Sodertalje
SE-151 85 Sodertalje
Sweden

Product information

14/08/2020 Qtrilmet - EMEA/H/C/004910 - IB/0003

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

  • to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.
  • when already being treated with metformin and saxagliptin and dapagliflozin.

Assessment history

How useful was this page?

Add your rating
Average
1 rating